Safety of Glycoprotein IIb-IIIa Inhibitors Used in Stroke-Related Treatment: A Systematic Review and Meta-Analysis
Background: Endovascular therapy and intravenous thrombolysis with recombinant tissue plasminogen activator are the 2 most recommended treatments for acute ischemic stroke (AIS). Glycoprotein (GP) IIb-IIIa inhibitors are short-acting selective reversible antiplatelet agents that emerged as promising...
Main Authors: | Xiaolin Zhu MD, Genmao Cao MD |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2020-07-01
|
Series: | Clinical and Applied Thrombosis/Hemostasis |
Online Access: | https://doi.org/10.1177/1076029620942594 |
Similar Items
-
Glycoprotein IIb-IIIa inhibitors – Do we still need them?
by: Vijayakumar Subban, et al.
Published: (2013-05-01) -
Inibidores da glicoproteína IIb/IIIa na prática clínica Inhibidores de la glicoproteína IIb/IIIa en la práctica clínica Glycoprotein IIb/IIIa inhibitors in clinical practice
by: Felipe Maia, et al.
Published: (2009-01-01) -
Glycoprotein IIb/IIIa inhibitors for cardiogenic shock complicating acute myocardial infarction: a systematic review, meta-analysis, and meta-regression
by: Carolina Saleiro, et al.
Published: (2020-11-01) -
Combined glycoprotein IIb/IIIa inhibitor therapy with ticagrelor for patients with acute coronary syndrome.
by: Zhi-Jiang Xie, et al.
Published: (2021-01-01) -
Concomitant Use of Glycoprotein IIb/IIIa Inhibitor and Streptokinase after Unsuccessful Rescue Angioplasty
by: José Marconi Almeida de Sousa, et al.
Published: (2002-04-01)